AAV-Hnf1α-mediated gene therapy prevented the development of hyperglycemia, hyperinsulinemia, increased glucose tolerance, and enhanced insulin secretion by the pancreatic islet apparatus, thereby reversing MODY3 in rodents. The gene discussed is HNF1A; the disease is maturity-onset diabetes of the young type 3.